Articles

EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma

Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research and Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China;Key Laboratory of Breast Cancer, and Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research and Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China;University of Chinese Academy of Sciences, Beijing, China
Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research and Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research and Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
University of Chinese Academy of Sciences, Beijing, China;Chemical Proteomics Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica and Chinese Academy of Sciences, Shanghai, China
Chemical Proteomics Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica and Chinese Academy of Sciences, Shanghai, China
Centre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, University of South Australia Cancer Research Institute, Adelaide, Australia
Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research and Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research and Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
Vol. 105 No. 4 (2020): April, 2020 https://doi.org/10.3324/haematol.2019.222935